key: cord-0849301-no0kdwi0 authors: Koutsakos, Marios; Lee, Wen Shi; Wheatley, Adam K; Kent, Stephen J; Juno, Jennifer A title: T follicular helper cells in the humoral immune response to SARS‐CoV‐2 infection and vaccination date: 2021-11-03 journal: J Leukoc Biol DOI: 10.1002/jlb.5mr0821-464r sha: 9a785d6b0e2103c796a8e8b403040f856c4419ed doc_id: 849301 cord_uid: no0kdwi0 Vaccination remains the most effective mechanism to reduce the impact of COVID‐19. Induction of neutralizing antibodies is a strong correlate of protection from infection and severe disease. An understanding of the cellular events that underpin the generation of effective neutralizing antibodies is therefore key to the development of efficacious vaccines that target emerging variants of concern. Analysis of the immune response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection and vaccination has identified circulating T follicular helper cells (cT(FH)) as a robust correlate of the neutralizing antibody response. Here, we discuss the analysis of cT(FH) cells and their lymphoid counterparts in human humoral immune responses during COVID‐19, and in response to vaccination with SARS‐CoV‐2 spike. We discuss the phenotypic heterogeneity of cT(FH) cells and the utility of cT(FH) subsets as informative biomarkers for development of humoral immunity. We posit that the analysis of the most effective cT(FH) will be critical to inducing durable immunity to new variants of SARS‐CoV‐2. Neutralizing antibodies can block the entry of SARS-CoV-2 into host cells, primarily by preventing spike from engaging ACE2. 2 There is increasing evidence that neutralizing antibodies are a strong correlate of protection from acquiring SARS-CoV-2 infection, with studies showing that plasma neutralization titers correlate strongly with vaccine efficacy. 3, 4 Numerous studies have also shown that passive transfer of neutralizing monoclonal antibodies into animal models provides sterilizing protection against experimental SARS-CoV-2 challenge. 5, 6 Most neutralizing antibodies target the RBD, 7 though neutralizing antibodies against N terminal domain of S1, and the fusion machinery within S2 have been reported. 8, 9 The development of humoral immunity is underpinned by the activation of SARS-CoV-2-specific B cells, which enter a germinal center (GC) reaction and differentiate into long-lived, antibody-secreting plasma cells or memory B cells (MBCs). While the majority of this response is derived from de novo priming of naïve B cells, there is some evidence that cross-reactive MBCs that recognize epitopes conserved in endemic hCoV can be recalled upon infection with SARS-CoV-2. 10, 11 However, such responses typically do not exhibit neutralizing activity. 10, 11 In addition to neutralization, antibodies against SARS-CoV-2 can exert antiviral activity by clearing free virions or infected cells via Fc effector functions including antibody-dependent phagocytosis (ADP) and antibody-dependent cellular cytotoxicity (ADCC). 12, 13 While most studies have focused on the Fc effector functions of S-specific antibodies, the M, N, and ORF3a proteins can all be detected on the surface of infected cells and be targeted by antibodies that mediate NK cell activation. 14 While it remains unclear the degree to which ADCC and ADP contribute to protection against SARS-CoV-2 in humans, several viral challenge studies in mice have shown the protective value of many RBD-and NTD-specific mAbs relies upon engagement with cellular Fc receptors in vivo. [15] [16] [17] During primary SARS-CoV-2 infection, neutralizing antibodies are generally detectable between 7 and 14 days following symptom onset, 18 peak around 23 days, and start to decline thereafter. 19 Sspecific antibodies that mediate Fc effector functions persist longer than neutralizing antibodies and could potentially contribute to protection upon reexposure. 12 The initial increase and subsequent decline of neutralizing antibodies have been linked to short-lived antibodysecreting cells (ASCs) that secrete high levels of antibodies in the early stages of infection and the rapidly decline afterward. 20 Despite this, Sand RBD-specific IgG antibodies are maintained for at least 11 months postinfection, 21, 22 with serologic neutralizing activity similarly maintained for at least 12 months. 22, 23 Critically, in individuals recovered from COVID-19, the bone marrow is populated by SARS-CoV-2 Sspecific ASCs (plasma cells) that are stable for at least 11 months. 21 Contrary to antibody titers, S-specific MBCs in peripheral blood increase in frequency during convalescence [22] [23] [24] [25] [26] [27] ), plateau at 8 months and are maintained for at least 12 months. 22 During that time, the MBC pool undergoes continued clonal evolution, with the emergence of new clones between 6 and 12 months and a gradual increase in VH gene mutational load. 22, [26] [27] [28] Notably, monoclonal antibodies isolated from convalescent COVID-19 individuals can exhibit increased binding affinity for S or RBD, and increased neutralizing potency over time. This evolution of the MBC compartment is strongly indicative of persistent GC activity and ongoing affinity maturation. 22, [26] [27] [28] Interestingly, N protein and SARS-CoV-2 viral RNA have been detected in intestinal biopsies of convalescent COVID-19 individuals taken ∼4 months after initial diagnosis, which suggest residual viral replication in the gut could be a potential source of antigen to support ongoing GC activity. Alternatively, antigen may be retained in the form of immune complexes on follicular dendritic cells within classical lymphoid tissues for prolonged support of ongoing GC activity. Overall, primary SARS-CoV-2 infection elicits a humoral immune response with hallmarks of prolonged GC activity, the generation of long-lived plasma cells, an evolving population of MBCs and serologic maintenance of potent neutralizing antibodies. The generation of effective humoral immune responses requires a well- 29, 30 and in some cases CD57. 31, 32 Expression of the transcriptional repressor Bcl-6 is a defining feature of T FH cells in lymphoid tissues. 31, 33, 34 T FH cells provide B cell cognate help via costimulatory molecules such as CD40L and indirectly by ICOS, as well as local secretion of cytokines including IL-21. The importance of IL-21 is highlighted by correlations between serum IL-21 levels and antibody responses to influenza vaccination. 35 The anatomic localization of GC T FH within lymphoid tissues hinders their sampling in many human cohort studies. However, a subset of circulating CD4 + T cells exists in blood with significant similarities to lymph-tissue T FH . These cells, known as circulating T FH (cT FH ), share surface expression of CXCR5 with lymphoid T FH and constitute ∼10% of the CD4 + T cell compartment in peripheral blood. 36 Despite their shared expression of CXCR5 and ability to support B cell activation, there are several key transcriptional and phenotypic differences between circulating and GC T FH . While cT FH development depends on the key T FH lineage-defining transcription factor Bcl-6, 37 cT FH cells exhibit low or no expression of Bcl-6, in stark contrast to GC T FH cells. 36, 38 Circulating T FH cells do, however, express c-Maf, 39 which can drive expression of CXCR5 and IL-21 in the absence of Bcl-6. 40 Additionally, cT FH typically have a quiescent phenotype and lack expression of activation markers such as PD-1, ICO,S or CD38, while retaining expression of CCR7. Nonetheless, transcriptomic, epigenetic, and TCR repertoire analyses have provided evidence to support a clonal and developmental overlap between GC T FH and cT FH . 41 Indeed, analysis of CXCR5 bright PD-1 bright CD4 + T cells from human thoracic duct lymph suggests this population is a trafficking intermediate between GC T FH and cT FH cells, which continually emigrate from lymphoid tissues. 41 Functionally, cT FH exhibit greater capacity for IL-21 and IL-10 secretion compared with CXCR5 -CD4 + T cells, thereby allowing them to provide superior B cell help in vitro compared with conventional memory CD4 + T cells, as determined by B cell survival and differentiation in ASCs. 36 Within the cT FH population, however, studies have Consistent with linkage between lymph node resident T FH and cT FH populations, an activated subpopulation of PD-1 + ICOS + CD38 + Ki67 + cT FH transiently emerges into the blood following viral infection or vaccination. 33, 38, [43] [44] [45] [46] Both peptide/MHC-II tetramers and antigen restimulation assays have demonstrated that this population contains CD4 + T cells specific for vaccine or infection-associated antigens. 38, 43, 46 The appearance of this cT FH population is temporally linked to the emergence of ASCs and correlates with the magnitude and qualitative aspects of the serologic response. This phenomenon has been widely observed following vaccination of human subjects with the inactivated influenza vaccine, 38 56 and malaria. 57, 58 It is clear that the analysis of cT FH cells in peripheral blood following vaccination or infection can provide important insights into humoral immunity. While activation of the overall cT FH population is a consistent biomarker of robust serologic responses to infection or vaccination, the relationship between the 3 distinct cT FH subsets and antibody production appears to be context dependent ( Figure 1 ). Activation of cT FH 1 cells has been associated with multiple aspects of humoral immunity (antibody titers and/or ASCs and/or antigen-specific B cells) for a number of viral infections and vaccines, including influenza, [43] [44] [45] 48 Yellow fever virus, 46 HIV, 54 and HCV. 55 On the other hand, vaccination with rVZV-ZEBOV, oral-inactivated E. coli, 53 or Plasmodium falciparum parasite protein antigens with AS01B adjuvant 52 results in activation of CXCR3 -cT FH 2/17 cells, which positively correlate with antibody responses to cognate antigens. Of note, although acute malaria infection drives activation of cT FH 1, cT FH 2, and cT FH 17 cells, this does not correlate with antibody responses in children 57 and higher activation of cT FH 1 cells is associated with an increased likelihood of symptomatic Plasmodium vivax infection. 58 Overall, the population of cT FH cells that emerges in peripheral blood after vaccination or infection is strongly associated with the development of protective humoral immunity. It has become evident that dividing this population into CXCR3/CCR6 subsets provides additional information and that these subsets maybe more reliable biomarkers than the total population. However, their ontogeny, their functional differences, and the context-specific correlations between cT FH subsets and humoral immunity warrant further investigation. Comparative analysis of the TCR repertoire analysis as well as singe-cell transcriptomic and epigenomic analyses could provide novel insights into cT FH polarization and help resolve discrepancies surrounding cT FH subsets. Many recent studies have analyzed the magnitude and phenotype of cT FH cell responses during the acute and convalescent phases of SARS-CoV-2 infection (Table 1) . 59 In the blood, activated cT FH (PD-1 + ICOS + ) 60-64 with increased expression of CD38 60 Although most studies have focused on S-specific cT FH cells, cT FH specific for N and M have also been studied. 65, 68, 69 Frequencies of cT FH cells specific for S, N, and M positively correlated with plasma neutralization activity as well as N-specific IgG antibodies. 69 Interestingly, polarization between cT FH 1, cT FH 2, and cT FH 17 subsets has been reported to differ for cT FH cells specific for different SARS-CoV-2 antigens, 68 although the significance of this observation is currently unclear. A potential impairment of T FH cells in some cases of severe COVID-19 has also been reported. Specifically, GC B cells and T FH cells were diminished in lymphoid tissues in a subset of deceased COVID-19 patients. 70 Additionally, a population of cT FH cells expressing cytotoxicity-associated transcripts like PRF1 and GZMB (encoding perforin and granzyme B respectively) and termed cytotoxic cT FH cells was increased in hospitalized versus nonhospitalized individuals and was correlated with lower antibody titers to S. 71 These observations are however contrary to the higher antibody titers observed in severe COVID-19, 60 since impaired T FH activity would be expected to result in lower antibody titers. These observations therefore warrant further investigation to understand the role and function of T FH cells in severe COVID-19 and whether they relate a specific subset of patients. In summary, the overall activation of cT FH cells during COVID-19 as well as their phenotypic polarization are correlates of neutralizing activity and B cell responses ( Figure 2) . What remains unclear, however, is the ontogeny of distinct cT FH subsets and their relationship to GC T FH activity. It is pertinent to further understand the potential of cT FH cells as biomarkers of the establishment and recall of humoral immunity to SARS-CoV-2, especially in the context of emerging variants of concern (VOCs) with increased potential for escape from humoral immunity. Vaccination with approved COVID-19 vaccines induces neutralizing antibodies that have been associated with protection from infection. Analysis of axillary draining lymph nodes after mRNA vaccination demonstrated potent GC reactions that persist for at least 12 weeks after booster immunisation. 72 Importantly, S-specific T FH cells are induced at those sites and correlate with S-specific GC B cells. 73, 74 Analysis of paired lymph node and blood samples has demonstrated that while S-specific cT FH cells with an activated phenotype (CD38 + HLA-DR + ICOS + ) peak within the first month before returning to a resting phenotype and declining in frequency, S-specific T FH cells in lymph nodes exhibit relatively constant frequencies for at least 60 days. 73 Although limited to a small number of donors, these analyses suggest that mRNA vaccines induce robust GC reactions that may underscore the strong immunogenicity profile of this vaccine. Vaccination of naïve (previously uninfected) individuals induces Sspecific cT FH cells 75-77 with a CXCR3 + phenotype 75 and the ability to produce IFNγ but not IL-17A. 78 The frequency of S-specific cT FH cells peaks within ∼1 month after vaccination and then wanes, contrary to S-specific T H 1 cells, the frequency of which is stable for at least 6 months. 77 The frequency of S-specific cT FH cells, as well as Sspecific conventional CD4 + T H 1 cells, at 2 weeks postvaccination correlates with neutralizing antibodies to spike as well as VOCs and with S and RBD-specific MBC responses at 1 month after vaccination. 77 This indicates a role of cT FH cells as biomarkers for the development of neutralizing antibodies and MBCs following vaccination with spike. Consistently, vaccination of individuals after recovery from COVID-19 induces greater S-specific cT FH responses than in naive individuals. 78 Importantly, the pre-vaccination frequency of S-specific cT FH cells in recovered individuals positively correlates with postvaccination neutralizing titers to ancestral viruses as well as VOCs. 76, 78 Overall, it is F I G U R E 2 Lymphoid and circulating T FH responses in COVID-19. SARS-CoV-2 antigen in the lymph nodes results in activation of antigen-specific B cells and T FH cells. Their interaction leads to the initiation of the germinal center reaction. This results in the development of memory B cells with increased somatic hypermutation (SHM) and increased affinity, as well as long-lived plasma cells that traffic to the bone marrow and provide a long-term source of neutralizing antibodies. A population of short-lived antibody-secreting cells (ASCs) appears in the circulation and provides a raid source of neutralizing antibodies. Concurrently, a population of activated (CD38 + , PD-1 + , ICOS + ) cT FH cells appears in the circulation. This population contains antigen-specific cT FH cells (not depicted). Although memory B cells and ASCs are primarily located in lymphoid tissues, they are typically measured in blood samples, where they correlate with activated cT FH cells. Activated cT FH cells also correlate with the development of neutralizing antibodies. These cT FH cells are a potential biomarker of T FH activity in lymphoid tissues but it remains to be determined if this population of cT FH cells are predictive of long-term neutralizing antibodies, or of the development of long-lived plasma cells and the prolonged evolution of the MBC pool. The figure was created with BioRender.com becoming evident that cT FH cells have an important role as biomarkers of humoral immunity following SARS-CoV-2 vaccination. It will be important to further characterize and understand lymphoid and circulating T FH cell responses following the administration of different recently developed vaccine platforms and if/how they differentially induce such responses, especially in the context of heterologous primeboost vaccination. There is increasing evidence that analysis of cT FH responses can provide critical insights into magnitude and qualitative aspects of the humoral immune response to SARS-CoV-2 infection and vaccination Coronavirus biology and replication: implications for SARS-CoV-2 Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Evidence for antibody as a protective correlate for COVID-19 vaccines Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Broad neutralization of SARS-related viruses by human monoclonal antibodies Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to nonneutralizing viral targets Decay of Fc-dependent antibody functions after mild to moderate COVID-19 Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans A dynamic COVID-19 immune signature includes associations with poor prognosis SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence Maturation and persistence of the anti-SARS-CoV-2 memory B cell response Evolution of antibody immunity to SARS-CoV-2 Prolonged evolution of the human B cell response to SARS-CoV-2 infection Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function The origins, function, and regulation of T follicular helper cells Human CD57+ germinal center-T cells are the major helpers for GC-B cells and induce class switch recombination With a little help from T follicular helper friends: humoral immunity to influenza vaccination Expansion of HIVspecific T follicular helper cells in chronic HIV infection Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation T follicular helper cells in human efferent lymph retain lymphoid characteristics CD4(+) T cells that help B cells -a proposal for uniform nomenclature Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenzaspecific B cell immunity Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination Circulating CXCR5(+)CD4(+) T follicular-like helper cell and memory B cell responses to human papillomavirus vaccines Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine Circulating follicular helper T cells and subsets are associated with immune response to hepatitis B vaccination The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy Circulating CXCR3(+) Tfh cells positively correlate with neutralizing antibody responses in HCV-infected patients Higher frequency of CD4+CXCR5+ICOS+PD1+ T follicular helper cells in patients with infectious mononucleosis Circulating Th1-Cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute Malaria in Children High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malaria Antigen-dependent multistep differentiation of T follicular helper cells and its role in SARS-CoV-2 infection and vaccination Integrated immune dynamics define correlates of COVID-19 severity and antibody responses Breadth of concomitant immune responses prior to patient recovery: a case report of nonsevere COVID-19 Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence Massachusetts consortium on pathogen readiness specimen working Bcl-6-Expressing T follicular helper cells and germinal centers in COVID-19 Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4(+) T cells in COVID-19 SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy Rapid induction of antigenspecific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination 2021) mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses The authors declare no conflicts of interest.